

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 January 2008 (03.01.2008)

PCT

(10) International Publication Number
WO 2008/000644 A1(51) International Patent Classification:
C07F 15/00 (2006.01)

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:
PCT/EP2007/055995

(22) International Filing Date: 18 June 2007 (18.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06116373.9 30 June 2006 (30.06.2006) EP(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PUENTENER, Kurt** [CH/CH]; Gellertstrasse 135, CH-4052 Basel (CH). **SCALONE, Michelangelo** [CH/CH]; Baslerstrasse 14, CH-4127 Birsfelden (CH).(74) Agent: **RAUBER, Beat**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2008/000644 A1

(54) Title: NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS




(I)

(57) Abstract: Disclosed are novel metathesis catalysts of the formula (I), a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis.

NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS


The invention relates to novel metathesis catalysts of the formula



a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis.

5 Metathesis reactions using ruthenium or other transition metal complexes as catalysts are meanwhile well known and have been widely applied in organic synthesis (see e.g. WO 2004/035596, WO 2002/14376 or EP-A 1180108).

A metathesis catalyst of the formula



10 is described by Barbasiewicz et al in *Organometallics*, published on Web June 17, 2006. The authors have shown that applying this catalyst in a ring closing metathesis reaction of *N,N*-diallyl-4-methylbenzenesulfonamide in dichloromethane at room temperature 41% of 1-(toluene-4-sulfonyl)-2,5-dihydro-1*H*-pyrrole was formed after a reaction time of 24h. Upon reworking under the same conditions, the conversion was 15 very poor (<3%) affording less than 1% of 1-(toluene-4-sulfonyl)-2,5-dihydro-1*H*-pyrrole and even at a higher reaction temperature (110°C in toluene) the activity of this catalyst remained poor.


- 2 -

Object of the present invention therefore was to provide superior metathesis catalysts.

It was surprisingly found that a substitution in alpha position of the nitrogen atom significantly improved the activity of the catalysts.

5 It could be shown that the ruthenium complexes of formula I have the potential to be useful catalysts in metathesis reactions such as in the ring closing or cross metathesis reactions.

The compounds of the present invention are characterized by the formula



10 wherein L is a neutral ligand;

X¹ and X² independently of each other are anionic ligands;

R¹ is C₁₋₆-alkyl, halogen-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyl, aryl, hydroxy, aryloxy, nitro, amino, mono-C₁₋₆-alkyl- or di-C₁₋₆-alkylamino, halogen, thio, C₁₋₆-alkylthio or SO₂-C₁₋₆-alkyl, SO₂-aryl, SO₃H, SO₃-C₁₋₆-alkyl or OSi(C₁₋₆-alkyl)₃ and
15 SO₂-N R' R'' wherein R' and R'' independently of each other have the meaning of hydrogen or C₁₋₆-alkyl or R' and R'' together with the N atom form a carbocycle;

R², R³, R⁴, R⁵ and R⁶ independently of each other have the meaning of hydrogen, C₁₋₆-alkyl, halogen-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyl, aryl, hydroxy, aryloxy, 20 nitro, amino, mono-C₁₋₆-alkyl- or di-C₁₋₆-alkylamino, halogen, thio, C₁₋₆-alkylthio or SO₂-C₁₋₆-alkyl, SO₂-aryl, SO₃H, SO₃-C₁₋₆-alkyl or OSi(C₁₋₆-alkyl)₃ and SO₂-N R' R'' wherein R' and R'' independently of each other have the meaning of hydrogen or C₁₋₆-alkyl or R' and R'' together with the N atom form a carbocycle,

Y is hydrogen, C₁₋₆-alkyl, C₂₋₆-alkenyl or aryl, or Y and R⁶ taken together to form a
25 (CH=CR) - or a -(CH₂)_n- bridge with n having the meaning of 2 or 3 and R as defined for R².

The present invention further includes a process for the preparation of the compounds of formula I and its use in metathesis reactions.

The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

5 The term "alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to six carbon atoms, preferably one to four carbon atoms. This term is further exemplified by radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, 1-adamantyl and the groups specifically exemplified herein.

10 The term "alkenyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent unsaturated aliphatic hydrocarbon radical of two to six carbon atoms, preferably two to four carbon atoms. This term is further exemplified by radicals as vinyl and propenyl, butenyl, pentenyl and hexenyl and their isomers. Preferred alkenyl radical is vinyl.

15 The term "halogen" refers to fluorine, chlorine, bromine and iodine. Preferred halogen is chlorine.

The term "halogen-C₁₋₆-alkyl" refers to a halogen substituted C₁₋₆-alkyl radical wherein halogen has the meaning as above. Preferred "halogen-C₁₋₆-alkyl" radicals are the fluorinated C₁₋₆-alkyl radicals such as CF₃, CH₂CF₃, CH(CF₃)₂, C₄F₉.

20 The term "alkoxy" refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to six carbon atoms, preferably 1 to four carbon atoms attached to an oxygen atom. Examples of "alkoxy" are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy. Preferred are the alkoxy groups specifically exemplified herein.

25 The alkyl chain of the alkoxy group can optionally be substituted, particularly mono-, di- or tri-substituted by alkoxy groups as defined above, preferably methoxy, or ethoxy or by aryl groups, preferably phenyl.

Preferred substituted alkoxy group is the benzyloxy group.

30 The term "alkyl carbonyl" refers to a C₁₋₆-alkylcarbonyl group preferably to a C₁₋₄-alkylcarbonyl group. It includes for example acetyl, propanoyl, butanoyl or pivaloyl. Preferred alkyl carbonyl group is acetyl.

The term "alkylthio" refers to the group R'-S-, wherein R' is C₁₋₆-alkyl, preferably C₁₋₄-alkyl e.g. methylthio or ethylthio. Preferred are the alkylthio groups specifically exemplified herein.

The term "SO₂- C₁₋₆-alkyl" refers to a sulfonyl substituted C₁₋₆-alkyl radical.

5 Preferred SO₂-C₁₋₆-alkyl radical is SO₂-methyl.

The term "SO₂- aryl" refers to a sulfonyl substituted aryl radical. Preferred SO₂-aryl radical is SO₂-phenyl.

10 The term "SO₂-N R'R''" refers to a sulfonyl substituted amino group N R'R'' wherein R' and R'' independently of each other have the meaning of hydrogen or C₁₋₆-alkyl or R' and R'' together with the N atom form a carbocycle. Preferred SO₂-N R'R'' radicals is SO₂-N(methyl)₂.

The term "OSi(C₁₋₆-alkyl)₃" refers to a tri- C₁₋₆-alkyl-substituted silyloxy group . Preferred meaning of OSi(C₁₋₆-alkyl)₃ are trimethylsilyloxy, triethylsilyloxy and t-butyldimethylsilyloxy.

15 The term "mono- or di-alkyl-amino" refers to an amino group, which is mono- or disubstituted with C₁₋₆-alkyl, preferably C₁₋₄-alkyl. A mono-C₁₋₆-alkyl-amino group includes for example methylamino or ethylamino. The term "di-C₁₋₆-alkyl-amino" includes for example dimethylamino, diethylamino or ethylmethylamino. Preferred are the mono- or di-C₁₋₄-alkylamino groups specifically exemplified herein. It is hereby 20 understood that the term "di-C₁₋₆-alkyl-amino" includes ring systems wherein the two alkyl groups together with the nitrogen atom to which they are attached form a 4 to 7 membered heterocycle which also may carry one further hetero atom selected from nitrogen, oxygen or sulfur.

25 The terms "amino" and "mono- or di-alkyl-amino" also encompass a group of the formula -NR'R''H⁺Z⁻ wherein R' and R'' are as above and Z⁻ is an anion such as a halogenide, particularly chloride or a sulfonate, particularly methansulfonate or p-toluenesulfonate.

The term "cycloalkyl" denotes a "C₃₋₇-cycloalkyl" group containing from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.



30 The term "aryl" relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be mono-, di-, tri- or multiply-substituted by halogen, hydroxy, CN, CF₃, NO₂, NH₂, N(H,alkyl), N(alkyl)₂, carboxy, aminocarbonyl, alkyl,

alkoxy, alkylcarbonyl, SO_2 -alkyl, SO_2 -aryl, SO_3H , SO_3 -alkyl, $\text{SO}_2\text{-NR}'\text{R}''$, aryl and/or aryloxy. Preferred aryl group is phenyl.

The term "aryloxy" relates to an aryl radical attached to an oxygen atom. The term "aryl" has the meaning as defined above. Preferred aryloxy group is phenoxy.


5 The term "heteroaryl" relates to a heterocyclic aryl radical containing 1 to 3 heteroatoms in the ring with the remainder being carbon atoms. Suitable heteroatoms include, without limitation, oxygen, sulfur, and nitrogen. Exemplary heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl, benzofuranyl, quinolinyl, and indolyl. Like the aryl group the heteroaryl
10 group can optionally be mono-, di-, tri- or multiply-substituted by halogen, hydroxy, CN , CF_3 , NO_2 , NH_2 , $\text{N}(\text{H,alkyl})$, $\text{N}(\text{alkyl})_2$, carboxy, aminocarbonyl, alkyl, alkoxy, alkylcarbonyl, SO_2 -alkyl, SO_2 -aryl, SO_3H , SO_3 -alkyl, $\text{SO}_2\text{-NR}'\text{R}''$, aryl and/or aryloxy.

The ligand L is a neutral ligand preferably selected from




15

IIa ;



IIb ;



IIc

wherein R^7 and R^8 independently of each other are C_{1-6} -alkyl, aryl, C_{2-6} - alkenyl or 1-adamantyl and

R^{9a-d} are independently of each other hydrogen, C_{1-6} -alkyl, C_{2-6} - alkenyl or aryl, or R^{9b} and R^{9c} or R^{9a} and R^{9d} taken together form a- $(\text{CH}_2)_4$ -bridge;

20 R^{10} is independently of each other C_{1-6} -alkyl, C_{3-7} -cycloalkyl, aryl or heteroaryl

In a preferred embodiment R^7 and R^8 are C_{1-6} -alkyl or a phenyl group which is di- or tri-substituted with C_{1-6} -alkyl.



R^7 and R^8 more preferably have the meaning of t-butyl, 1-adamantyl, isopropyl, 2, 6-diisopropylphenyl or 2, 4, 6-trimethylphenyl most preferably 2, 4, 6-trimethylphenyl.

25 In a preferred embodiment R^{9a} and R^{9c} are methyl or phenyl and R^{9b} and R^{9d} are hydrogen, or R^{9a} and R^{9c} or R^{9b} and R^{9d} are taken together to form a- $(\text{CH}_2)_n$ - bridge with n having the meaning of 5 or 6. Its hereby understood that if chiral carbon atoms are present, both the racemic and the enantiomerically pure form are comprised.

- 6 -

In a further preferred embodiment R^{9a-d} is hydrogen.

In a further preferred embodiment L is



wherein R^7 and R^8 are as described above.

5 In a further preferred embodiment R^{10} is cyclohexyl.

As anionic ligand X^1 and X^2 a halogenide or a pseudo halogenide such as cyanide, a rhodanide, a cyanate, an isocyanate, acetate or trifluoroacetate may be selected. Preferred anionic ligand for X^1 and X^2 is a halogenide, whereas chloro is the most preferred anionic ligand.

10 In a further preferred embodiment R^1 is C_{1-6} -alkyl, halogen- C_{1-6} -alkyl or aryl. R^1 more preferably is methyl, trifluoromethyl, phenyl, ortho-tolyl or 2,6-dimethylphenyl.


In a further preferred embodiment R^2 , R^4 , R^5 and R^6 are hydrogen.







15 R^3 preferably is hydrogen, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl, nitro, amino and halogen. More preferred R^3 stands for chloro, hydroxy, benzyloxy, amino, nitro and acetyl.

The following compounds represent the most preferred representatives of the present invention.


Abbreviations: ImH_2Mes = 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene; ImMes = 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazoylidene

20 Table of catalysts tested:


Catalyst Structure	Chemical Name
	$[\text{RuCl}_2(\text{ImH}_2\text{Mes})(8\text{-quinolinylmethylene})]$ (Comparison example)

	<p>[RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]</p>
	<p>[RuCl₂(ImH₂Mes)((4-hydroxy-2-phenyl-8-quinolinyl)methylene)]</p>
	<p>[RuCl₂(ImH₂Mes)((4-chloro-8-quinolinyl)methylene)] (Comparison example)</p>
	<p>[RuCl₂(ImH₂Mes)((2-methyl-8-quinolinyl)methylene)]</p>
	<p>[RuCl₂(tricyclohexylphosphine)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]</p>
	<p>[RuCl₂(ImMes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]</p>

The present invention also comprises a process for the preparation of a compound of the formula I which comprises the transformation of a Ru-precursor compound of the formula III



5 wherein X¹ and X² are as defined, Cy has the meaning of cyclohexyl and Ph is phenyl with a compound of formula IV




wherein R¹ to R⁶ have the meaning as above.

10 The conversion as a rule takes place in an organic solvent like toluene, benzene, tetrahydrofuran or dichloromethane in the presence of a copper salt, preferably copper chloride at a temperature of about 0°C to 60°C.

The compounds of formula IV can be prepared by several well known cross-coupling reactions which are e.g. described in F. Diederich and P. J. Stang in 'Metal-catalyzed cross-coupling reactions' Wiley-VCH, 1998 or J. March in 'Advanced organic chemistry' Wiley-VCH, 1992 starting from commercially available or easy accessible compounds of formula V with e.g. vinylstannanes, ethylene, vinylboronates, vinylboranes, vinyl Grignard reagents or under Wittig, Wittig-Horner, Wittig-Horner-Emmons, Tebbe or Peterson conditions starting from commercially available aldehydes of formula VI.

- 9 -



wherein Z is halogen or trifluoromethansulfonyloxy and R¹ to R⁶ have the meaning as above.

5 The compounds of the present invention can be used in metathesis reactions particularly in ring closing or cross metathesis reactions. Though it is apparent for the skilled in the art that reaction conditions have to be adapted for each substrate, the following conditions can as a rule be applied.

10 Ring closing and cross metathesis reactions are usually performed in an inert organic solvent such as in toluene, xylene, mesitylene, and dichloromethane and at reaction temperatures from 20°C to 180°C. Catalyst concentration is commonly selected between 0.1 mol% and 10 mol%.

The following examples illustrate the invention without limiting it.

15

Examples

Abbreviations: ImH₂Mes = 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene; ImMes = 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolylidene

Table of Catalysts tested:

Catalyst Structure	Chemical Name
	[RuCl ₂ (ImH ₂ Mes)(8-quinolinylmethylene)] (Comparison example)
	[RuCl ₂ (ImH ₂ Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]
	[RuCl ₂ (ImH ₂ Mes)((4-hydroxy-2-phenyl-8-quinolinyl)methylene)]
	[RuCl ₂ (ImH ₂ Mes)((4-chloro-8-quinolinyl)methylene)] (Comparison example)
	[RuCl ₂ (ImH ₂ Mes)((2-methyl-8-quinolinyl)methylene)]
	[RuCl ₂ (tricyclohexylphosphine)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]
	[RuCl ₂ (ImH ₂ Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]

Synthesis of Catalysts: Examples 1-11

Example 1

[RuCl₂(ImH₂Mes)(8-quinolinylmethylene)]

A suspension of 500 mg (0.59 mmol) of [RuCl₂(PCy₃)(ImH₂Mes)(phenylmethylene)] (commercially available from Sigma-Aldrich Inc., St. Louis, USA), 60 mg (0.61 mmol) copper chloride and 100 mg (0.64 mmol) 8-vinylquinoline (prepared according to G.T. Crisp, S. Papadopoulos, *Aust. J. Chem.* 1989, 42, 279-285) in 40 ml methylene chloride was stirred at room temperature for 90 min. The reaction mixture was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 2:1) to yield 255 mg (70%) of the title compound as green crystals. MS: 584.4 (M-Cl⁺). ¹H-NMR (300 MHz, CD₂Cl₂): 2.36 (s, 6H); 2.40 (s, 12H); 4.04 (s, 4H); 7.01 (s, 4H); 7.19 (dd, J=8.4, 4.9Hz, 1H); 7.34 (t, J=7.7Hz, 1H); 7.51 (d, J=7.1Hz, 1H); 8.08-8.18 (m, 2H); 8.26 (dd, J=4.8, 1.3Hz, 1H); 16.95 (s, 1H). Anal. calcd. for C₃₁H₃₃N₃Cl₂Ru: C, 60.09; H, 5.37; N, 6.78; Cl, 11.44. Found: C, 60.06; H, 5.75; N, 6.16; Cl, 10.90.

Example 2

4-Chloro-2-trifluoromethyl-8-vinyl-quinoline

A suspension of 2.00 g (6.25 mmol) 8-bromo-4-chloro-2-trifluoromethylquinoline (commercially available from Maybridge, Cornwall, UK), 258 mg (0.31 mmol) PdCl₂dppfCH₂Cl₂, 1.29 g (9.37 mmol) potassium vinyl tetrafluoroborate and 0.88 ml (6.28 mmol) triethylamine in 40 ml ethanol was heated at reflux for 3 h. The resulting yellow suspension was filtered and the filtrate evaporated to dryness. The residue was suspended in ethyl acetate, filtered and the filtrate extracted with water. The organic layer was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane) to yield 1.17 g (72%) of the title compound as white crystals. MS: 257.1 (M⁺). ¹H-NMR (300 MHz, CDCl₃): 5.58 (dd, J=11.1, 1.1Hz, 1H); 6.07 (dd, J=17.8, 1.1Hz, 1H); 7.75 (t, J=7.7Hz, 1H); 7.81 (s, 1H); 7.99 (dd, J=17.8, 11.1Hz, 1H); 8.09 (d, J=7.2Hz, 1H); 8.23 (d, J=8.4Hz, 1H).

Example 3

[RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]

A suspension of 1.39 g (1.64 mmol) of [RuCl₂(PCy₃)(ImH₂Mes)(phenylmethylene)], 0.17 g (1.80 mmol) copper chloride and 464 mg (1.69 mmol) 4-chloro-2-trifluoromethyl-8-vinyl-quinoline in 100 ml methylene chloride was stirred at 30°C for 90

min. The reaction mixture was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 5:2) to yield 278 mg (24%) of the title compound as green crystals. MS: 721.2 (M^+). 1H -NMR (300 MHz, CD_2Cl_2): 2.85 (s, 6H); 2.40 (s, 12H); 4.05 (s, 4H); 7.01 (s, 4H); 7.54 (s, 1H); 7.56 (t, $J=7.7$ Hz, 1H); 5 7.65 (d, $J=6.8$ Hz, 1H); 8.51 (d, $J=8.4$ Hz, 1H); 16.70-17.10 (br, 1H).

Example 4

2-Phenyl-8-vinyl-quinoline-4-ol

A suspension of 500 mg (1.67 mmol) 8-bromo-2-phenyl-quinoline-4-ol (commercially available from Ubichem Research Ltd, Budapest, Hungary), 97 mg (0.09 10 mmol) $Pd(PPh_3)_4$, 71 mg (1.67 mmol) lithium chloride and 528 mg (1.67 mmol) tributylvinyl stannane in 20 ml dioxane was heated at 90°C for 16 h. The resulting yellow suspension was filtered and the filtrate evaporated to dryness. The residue was suspended in ethyl acetate, filtered and the filtrate extracted with water. The organic layer was evaporated to dryness and the isolated crude product purified by silica gel 15 chromatography (ethyl acetate) to yield 178 mg (43%) of the title compound as yellowish crystals. 1H -NMR (300 MHz, $CDCl_3$): 5.59 (d, $J=11.1$ Hz, 1H); 5.75 (d, $J=17.4$ Hz, 1H); 6.42(s, 1H); 7.04 (dd, $J=17.4$, 11.1Hz, 1H); 7.23 (t, $J=8.1$ Hz, 1H); 7.40-7.60 (m, 6H); 8.21 (d, $J=8.1$ Hz, 1H); 8.70 (br, 1H).

Example 5

20 [$RuCl_2(ImH_2Mes)((4$ -hydroxy-2-phenyl-8-quinolinyl)methylene)]

A suspension of 100 mg (0.12 mmol) of [$RuCl_2(PCy_3)(ImH_2Mes)(phenylmethylene)$], 12 mg (0.12 mmol) copper chloride and 100 mg (0.12 mmol) 2-phenyl-8-vinyl-quinoline-4-ol in 11 ml methylene chloride was stirred at 40°C for 1 h. The reaction mixture was evaporated to dryness and the isolated crude product purified by silica gel 25 chromatography (hexane / ethyl acetate 2:1) to yield 51 mg (61%) of the title compound as green crystals. MS: 711.1 (M^+). 1H -NMR (300 MHz, CD_2Cl_2): 2.32 (s, 12H); 2.41 (s, 6H); 3.90 (s, 4H); 6.12-6.28 (br, 1H); 6.80-6.92 (m, 2H); 6.98 (s, 4H); 7.04-7.14 (m, 1H); 7.19 (t, $J=7.1$ Hz, 1H); 7.29 (d, $J=6.9$ Hz, 1H); 7.35 (d, $J=7.5$ Hz, 2H); 7.49 (d, $J=7.1$ Hz, 1H); 7.80-8.00 (br, 1H); 17.34 (s, 1H).

30

Example 6

4-Chloro-8-vinyl-quinoline

A suspension of 975 mg (4.02 mmol) 8-bromo-4-chloroquinoline (commercially available from Ubichem Research Ltd, Budapest, Hungary), 166 mg (0.20 mmol)

PdCl₂dppfCH₂Cl₂, 833 mg (6.00 mmol) potassium vinyl tetrafluoroborate and 0.57 ml (4.10 mmol) triethylamine in 20 ml ethanol was heated at reflux for 3 h. The resulting yellow suspension was filtered and the filtrate evaporated to dryness. The residue was suspended in ethyl acetate, filtered and the filtrate extracted with water. The organic layer 5 was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 9:1) to yield 207 mg (27%) of the title compound as white crystals. MS: 189.1 (M⁺). ¹H-NMR (300 MHz, CDCl₃): 5.53 (d, J=11.1Hz, 1H); 5.95 (d, J=17.7Hz, 1H); 7.51 (d, J=4.6Hz, 1H); 7.63 (t, J=7.9Hz, 1H); 7.96 (dd, J=17.7, 11.1 Hz, 1H); 7.97 (d, J=7.1Hz, 1H); 8.19 (d, J=8.5Hz, 1H); 8.80 (d, J=4.6 Hz, 1H).

10 **Example 7 (for comparison)**

[RuCl₂(ImH₂Mes)((4-chloro-8-quinoliny)ethylene)]

A suspension of 790 mg (0.93 mmol) of [RuCl₂(PCy₃)(ImH₂Mes)(phenylmethylene)], 95 mg (0.96 mmol) copper chloride and 196 mg (1.03 mmol) 4-chloro-8-vinyl-quinoline in 70 ml methylene chloride was stirred at 30°C for 90 min. The reaction 15 mixture was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 5:2) and finally digested in 20 ml pentane at room temperature for 30 min to yield 311 mg (51%) of the title compound as green crystals. MS: 655.0 (M⁺). ¹H-NMR (300 MHz, CD₂Cl₂): 2.35 (s, 6H); 2.39 (s, 12H); 4.04 (s, 4H); 7.00 (s, 4H); 7.25 (d, J=5.3Hz, 1H); 7.43 (dd, J=8.2, 7.3Hz, 1H); 7.56 (dd, J=7.1, 0.7Hz, 1H); 8.13 (d, J=5.3Hz, 1H); 8.41 (dd, J=8.2, 0.7Hz, 1H); 16.95 (s, 1H). Anal. calcd. for 20 C₃₁H₃₂N₃Cl₃Ru: C, 56.93; H, 4.93; N, 6.42; Cl, 16.26. Found: C, 56.59; H, 5.04; N, 6.02; Cl, 15.49.

Example 8

2-Methyl-8-vinyl-quinoline

A suspension of 4.80 g (21.60 mmol) 8-bromo-2-methylquinoline (commercially 25 available from ACB Block Ltd, Moscow, Russia), 0.89 g (1.10 mmol) PdCl₂dppfCH₂Cl₂, 4.48 g (32.40 mmol) potassium vinyl tetrafluoroborate and 3.10 ml (22.10 mmol) triethylamine in 150 ml ethanol was heated at reflux for 3 h. The resulting yellow suspension was filtered and the filtrate evaporated to dryness. The residue was suspended 30 in ethyl acetate, filtered and the filtrate extracted with water. The organic layer was evaporated to dryness and the isolated crude product purified by silica gel chromatography (CH₂Cl₂ / ethyl acetate 98:2) to yield 2.68 g (73%) of the title compound as a colorless oil. MS: 169.1 (M⁺). ¹H-NMR (300 MHz, CDCl₃): 2.74 (s, 1H); 5.47 (dd, J=11.1, 1.6Hz, 1H); 5.97 (dd, 17.9, 1.6 Hz, 1H); 7.24 (d, J=8.4Hz, 1H); 7.43 (t, J=7.7Hz,

1H); 7.66 (dd, $J=8.1, 1.2$ Hz, 1H); 7.87 (dd, $J=7.3, 1.2$ Hz, 1H); 7.97 (d, $J=8.4$ Hz, 1H); 8.05 (dd, $J=17.9, 11.1$ Hz, 1H).

Example 9

[RuCl₂(ImH₂Mes)((2-methyl-8-quinolinyl)methylene)]

5 A suspension of 218 mg (0.26 mmol) of [RuCl₂(PCy₃)(ImH₂Mes)(phenylmethylene)], 26 mg (0.26 mmol) copper chloride and 49 mg (0.29 mmol) 2-methyl-8-vinyl-quinoline in 17 ml methylene chloride was stirred at 30°C for 90 min. The reaction mixture was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 7:3) and finally digested in 15 ml hexane at room 10 temperature for 30 min to yield 157 mg (96%) of the title compound as green crystals. MS: 632.9 (M⁺). ¹H-NMR (300 MHz, C₆D₆): 2.15 (s, 3H); 2.29 (s, 6H); 2.64 (s, 12H); 3.49 (s, 4H); 6.30 (d, $J=8.4$ Hz, 1H); 6.80 (t, $J=7.3$ Hz, 1H); 6.98 (s, 4H); 7.10 (d, $J=8.4$ Hz, 1H); 7.40 (d, $J=8.1$ Hz, 1H); 7.52 (d, $J=7.0$ Hz, 1H), 17.15-17.32 (br, 1H). Anal. calcd. for C₃₂H₃₅N₃Cl₂Ru: C, 60.66; H, 5.57; N, 6.63; Cl, 11.19. Found: C, 60.33; H, 5.58; N, 6.27; Cl, 10.90.

Example 10

[RuCl₂(tricyclohexylphosphine)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]

20 A suspension of 3.07 g (3.73 mmol) of [RuCl₂(PCy₃)₂(phenylmethylene)] (commercial available from Sigma-Aldrich Inc., St. Louis, USA), 380 mg (3.84 mmol) copper chloride and 1.06 g (4.10 mmol) 4-chloro-2-trifluoromethyl-8-vinyl-quinoline in 135 ml methylene chloride was stirred at 30°C for 90 min. The reaction mixture was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 2:1) and finally digested in 50 ml pentane at room 25 temperature for 30 min to yield 429 mg (17%) of the title compound as dark green crystals. MS: 697.0 (M⁺). ³¹P-NMR (121 MHz, C₆D₆): 54.2 ppm. ¹H-NMR (300 MHz, C₆D₆): 1.18-2.35 (m, 30H); 2.60 (q, $J=12.0$ Hz, 3H); 6.82 (t, $J=6.0$ Hz, 1H); 7.01 (d, $J=3.0$ Hz, 1H); 7.55 (d, $J=6.0$ Hz, 1H); 7.89 (d, $J=6.0$ Hz, 1H); 17.80-17.90 (m, 1H).

Example 11

30 [RuCl₂(ImMes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)]

A suspension of 1.30 g (1.54 mmol) of [RuCl₂(PCy₃)(ImMes)(phenylmethylene)] (prepared according to J. Huang, E. Stevens, S. Nolan, J. Petersen, *J. Am. Chem. Soc.* 1999, 121, 2674-2678), 0.15 g (1.54 mmol) copper chloride and 435 mg (1.68 mmol) 4-chloro-

2-trifluoromethyl-8-vinyl-quinoline in 100 ml methylene chloride was stirred at 30°C for 90 min. The reaction mixture was evaporated to dryness and the isolated crude product purified by silica gel chromatography (hexane / ethyl acetate 5:2) to yield 260 mg (24%) of the title compound as orange crystals. MS: 719.0 (M⁺). ¹H-NMR (300 MHz, C₆D₆): 5 2.33 (s, 6H); 2.46 (s, 12H); 6.30 (s, 2H); 6.76 (dd, J=9.0, 6.0Hz, 1H); 6.83 (s, 1H); 6.97 (s, 4H); 7.58 (d, J=6.0Hz, 1H); 7.85 (d, J=9.0Hz, 1H); 17.31-17.36 (m, 1H).

Application of Catalysts in Ring Closing Metathesis: Examples 12-18

Example 12

1-(Toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole

10 A solution of 257 mg (1.02 mmol) N,N-diallyl 4-methylbenzenesulfonamide (prepared according to S. Varray, R. Lazaro., J. Martinez, F. Lamaty, *Organometallics* 2003, 22, 2426-2435) and 19 mg (0.03 mmol) [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] in 5 ml toluene was stirred at 110°C. To monitor the conversion and selectivity, 0.2-ml samples were taken after 1 h and 4 h. Each sample 15 was filtered over a silica gel pad, the filtrate was evaporated to dryness and analyzed by GC (column: DB-1701; injector: 260°C; detector: 260°; oven: 70 to 250°C / 5°C per min; carrier gas: H₂ (60 kPa); retention times: 15.5 min N,N-diallyl 4-methylbenzenesulfonamide, 24.5 min 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole, 25.5 min 1-(toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole). After 1 h (98% conversion), 20 96 % of the title compound and 2 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole and after 4 h (100% conversion) 92% of the title compound and 8% of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole were formed. ¹H-NMR of 1-(toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole (300 MHz, C₆D₆): 2.43 (s, 3H); 4.12 (s, 4H); 5.65 (s, 2H); 7.32 (d, J=8.3Hz, 2H); 7.73 (d, J=8.3Hz, 2H). ¹H-NMR of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole (300 MHz, C₆D₆): 2.40-2.55 (m, 2H); 2.43 (s, 3H); 3.48 (t, J=8.9Hz, 2H); 25 5.10-5.15 (m, 1H); 8.35-8.40 (m, 1H); 7.32 (d, J=8.3Hz, 2H); 7.67 (d, J=8.3Hz, 2H).

Example 13 (for comparison)

1-(Toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole

In an analogous manner to Example 12 but in the presence of 17 mg (0.03 mmol) 30 [RuCl₂(ImH₂Mes)((4-chloro-8-quinolinyl)methylene)] instead of [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, after 1 h (7% conversion), 7 % of the title compound and after 4 h (15% conversion), 14% of the title compound and 1 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole were formed.

Example 14 (for comparison)**1-(Toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole**

a) In an analogous manner to Example 12 but in the presence of 16 mg (0.03 mmol) [RuCl₂(ImH₂Mes)(8-quinolinylmethylene)] instead of [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, after 1 h (7% conversion), 5 7 % of the title compound and after 4 h (31% conversion), 28% of the title compound and 3 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole were formed.

b) According to Barbasiewicz et al. (*Organometallics*, published on Web June 17, 2006), a solution of 88 mg (0.35 mmol) *N,N*-diallyl 4-methylbenzenesulfonamide and 10 11.2 mg (0.018 mmol) [RuCl₂(ImH₂Mes)(8-quinolinylmethylene)] in 17.5 ml dichloromethane was stirred at room temperature. To monitor the conversion and selectivity, 0.2-ml samples were taken after 4 h and 24 h. Each sample was filtered over a silica gel pad, the filtrate was evaporated to dryness and analyzed by GC as described in Example 12. After 4 h (2% conversion), 0.6 % of the title compound and 0.3 15 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole and after 24 h (3% conversion) 1.5% of the title compound and 0.5% of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole were formed.

Example 15**1-(Toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole**

In an analogous manner to Example 12 but in the presence of 18 mg (0.03 mmol) 20 [RuCl₂(ImH₂Mes)((4-hydroxy-2-phenyl-8-quinolinyl)methylene)] instead of [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, after 1 h (99% conversion) 98 % of the title compound and 1 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole and after 4 h (100% conversion), 99 % of the title 25 compound and 1 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-pyrrole were formed.

Example 16**1-(Toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole**

In an analogous manner to Example 12 but in the presence of 18 mg (0.03 mmol) 30 [RuCl₂(ImH₂Mes)((2-methyl-8-quinolinyl)methylene)] instead of [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, after 1 h (22%

conversion) 11 % of the title compound and after 4 h (66% conversion), 22 % of the title compound and 5 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1*H*-pyrrole were formed.

Example 17

1-(Toluene-4-sulfonyl)-2,5-dihydro-1*H*-pyrrole

5 In an analogous manner to Example 12 but in the presence of 16 mg (0.03 mmol) [RuCl₂(tricyclohexylphosphine)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] instead of [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, after 1 h (11% conversion) 7 % of the title compound and 1 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1*H*-pyrrole and after 4 h (42% conversion), 25 % of the title 10 compound and 1 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1*H*-pyrrole were formed.

Example 18

1-(Toluene-4-sulfonyl)-2,5-dihydro-1*H*-pyrrole

In an analogous manner to Example 12 but in the presence of 20 mg (0.03 mmol) [RuCl₂(ImMes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] instead of 15 [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, after 1 h (53% conversion) 11 % of the title compound and 11 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1*H*-pyrrole, after 4 h (100% conversion), 54 % of the title compound and 2 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1*H*-pyrrole and after 20 h (100% conversion), 1 % of the title compound and 64 % of 1-(toluene-4-sulfonyl)-2,3-dihydro-1*H*-pyrrole were formed. 20

Application of Catalysts in Cross Metathesis: Examples 19-20

Example 19

(E)/(Z)-Diethyl 2-[3-cyano-2-propenyl]malonate

A solution of 100.0 mg (0.48 mmol) diethyl allylmalonate, 77.4 mg (1.45 mmol) 25 acrylonitrile and 35.0 mg (0.05 mmol) [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] in 5 ml toluene was stirred at 110°C. To monitor the conversion and selectivity, 0.05-ml samples were taken after 3h and 40 h. Each sample was filtered over a silica gel pad, the filtrate was evaporated to dryness and analyzed by GC (column: HP-5, 5% phenyl methyl siloxan (Agilent 19091-413); injector: 250°C; detector: 30 250°C; oven: 100 to 150°C / 5°C per min, 5 min at 150°C, 150 to 200°C / 5°C per min and 200 to 300°C / 20°C per min; carrier gas: He (0.46 bar); retention times: 9.2 min diethyl allylmalonate, 17.5 min (Z)-diethyl 2-[3-cyano-2-propenyl]malonate and 18.8 min (E)-

diethyl 2-[3-cyano-2-propenyl]malonate). After 3 h (66% conversion), 57 % of the title compound and after 40 h (94% conversion) 83% of the title compound as an (E):(Z) mixture of 1:2 was formed. After evaporation of the solvent under reduced pressure, the crude product was purified by silica gel chromatography (cyclohexane / ethyl acetate 8:2) 5 to yield 65.1 mg (60%) of the title compound as a (E):(Z) mixture of 1:2. MS: 226.3 (M⁺). ¹H-NMR of diethyl 2-[3-cyano-2-propenyl]malonate (300 MHz, C₆D₆): (Z)-isomer: 1.29 (t, J=7.1Hz, 6H); 2.99 (td, J=7.1, 1.5Hz, 2H); 3.51 (t, J=7.0 Hz, 1H); 4.20-4.24 (m, 4H); 5.40-5.42 (m, 1H); 6.54 (m, 1H). (E)-isomer: 1.28 (t, J=7.1Hz, 6H); 2.79 (td, J=7.1, 1.5Hz, 2H); 3.46 (t, J=7.1 Hz, 1H); 4.20-4.24 (m, 4H); 5.40-5.42 (m, 1H); 6.68 (m,1H).


10 **Example 20**

(E)/(Z)-Diethyl 2-[3-cyano-2-propenyl]malonate

In an analogous manner to Example 19 but in the presence of 34.9 mg (0.05 mmol) [RuCl₂(ImMes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] instead of [RuCl₂(ImH₂Mes)((4-chloro-2-trifluoromethyl-8-quinolinyl)methylene)] as catalyst, 15 after 19 h (80% conversion), 48 % of the title compound and after 40 h (87% conversion) 49% of the title compound as an (E):(Z) mixture of 1:2 was formed.

Claims

1. A compound of the formula I



I

5 wherein L is a neutral ligand;

X¹ and X² independently of each other are anionic ligands;

R¹ is C₁₋₆-alkyl, halogen-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyl, aryl, hydroxy, aryloxy, nitro, amino, mono-C₁₋₆-alkyl- or di-C₁₋₆-alkylamino, halogen, thio, C₁₋₆-alkylthio or SO₂-C₁₋₆-alkyl, SO₂-aryl, SO₃H, SO₃-C₁₋₆-alkyl or OSi(C₁₋₆-alkyl)₃ and SO₂-N¹⁰R'R" wherein R' and R" independently of each other have the meaning of hydrogen or C₁₋₆-alkyl or R' and R" together with the N atom form a carbocycle;

R², R³, R⁴, R⁵ and R⁶ independently of each other have the meaning of hydrogen, C₁₋₆-alkyl, halogen-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyl, aryl, hydroxy, aryloxy, nitro, amino, mono-C₁₋₆-alkyl- or di-C₁₋₆-alkylamino, halogen, thio, C₁₋₆-alkylthio or SO₂-C₁₋₆-alkyl, SO₂-aryl, SO₃H, SO₃-C₁₋₆-alkyl or OSi(C₁₋₆-alkyl)₃ and SO₂-N R'R" wherein R' and R" independently of each other have the meaning of hydrogen or C₁₋₆-alkyl or R' and R" together with the N atom form a carbocycle;


Y is hydrogen, C₁₋₆-alkyl, C₂₋₆-alkenyl or aryl, or Y and R⁶ taken together to form a (CH=CR) - or a -(CH₂)_n- bridge with n having the meaning of 2 or 3 and R is as defined for R².

2. A compound according to claim 1 wherein


L is a neutral ligand selected from

—P(R¹⁰)₃:


- 20 -



IIa ;



IIb ;




IIc

wherein R⁷ and R⁸ independently of each other are C₁₋₆-alkyl, aryl, C₂₋₆- alkenyl or 1-adamantyl and


R^{9a-d} are independently of each other hydrogen, C₁₋₆-alkyl, C₂₋₆- alkenyl or aryl, or 5 R^{9b} and R^{9c} or R^{9a} and R^{9d} taken together form a -(CH₂)₄-bridge;

R¹⁰ is independently of each other C₁₋₆-alkyl, C₃₋₇-cycloalkyl, aryl or heteroaryl.

3. A compound according to claim 2 wherein L is



IId



IIe

wherein R⁷ and R⁸ are as described above.

10 4. A compound according to claims 2 or 3 wherein R⁷ and R⁸ is 2, 4, 6-trimethylphenyl.

5. A compound according to claims 1 to 4 wherein X¹ and X² independently of each other are a halogen.

6. A compound according to claim 5 wherein X¹ and X² is chloro.


15 7. A compound according to claims 1 to 6 wherein R¹ is C₁₋₆- alkyl, halogen C₁₋₆- alkyl or aryl.

8. A compound according to claim 7 wherein R¹ is methyl, trifluoromethyl, orthotolyl, 2,6-dimethylphenyl or phenyl.


9. A compound according to claims 1 to 8 wherein R³ is hydrogen, hydroxy, C₁₋₆- alkoxy, nitro, amino and halogen.

20 10. A compound according to claims 1 to 9 wherein R², R⁴, R⁵ and R⁶ are hydrogen.

11. A process for the preparation of a compound of the formula 1 according to claims 1 to 10 which comprises the transformation of a Ru-precursor compound of the formula



5 wherein X¹ and X² are as defined, Cy has the meaning of cyclohexyl and Ph is phenyl with a compound of formula IV



wherein R¹ to R⁶ have the meaning as above.

12. The use of a compound of the formula I according to claims 1 to 11 in
10 metathesis reactions.

13. The use of a compound of the formula I according to claim 12, in ring closing metathesis reactions.

14. The use of a compound of the formula I according to claim 12, in cross metathesis reactions.

15. The invention as hereinbefore described.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/055995

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07F15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MICHA BARBASIEWICZ, ANNA SZADKOWSKA, ROBERT BUJOK, AND KAROL GRELA: "Structure and Activity Peculiarities of Ruthenium Quinoline and Quinoxaline Complexes: Novel Metathesis Catalysts" ORGANOMETALLICS, 25 (15), 3599 -3604, 2006, 17 June 2006 (2006-06-17), XP002451178 cited in the application the whole document figure 8</p> <p>-----</p>	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search 9 November 2007	Date of mailing of the international search report 20/11/2007
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Bader, Karl Günther

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2007/055995

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-15

A compound of formula I, its preparation and use, wherein
 $Y=H$

2. claims: 1-15

A compound of formula I, its preparation and use, wherein
 $Y=C1-C6$ alkyl or $C2-C6$ alkenyl

3. claims: 1-15

A compound of formula I, its preparation and use, wherein Y
and R6 are taken together to form a bridge as specified in
claim 1.

4. claims: 1-15

A compound of formula I, its preparation and use, wherein
 $Y=aryl$

5. claim: 11

The preparation of a compound of formula I, wherein A in
Formula IV is not N
